| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 28, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob47 | SVP Corp Admin Center | Sell | 1,520 | $20.49 | $31,140.24 | -14.7% | |
| Nov 27, 2018 | AQST Aquestive Therapeutics, Inc. | Braender Lori J | General Counsel | Buy | 1,000 | $10.57 | $10,570.00 | New | |
| Nov 27, 2018 | AQST Aquestive Therapeutics, Inc. | Kendall Keith J | CEO And President | Buy | 1,000 | $9.87 | $9,870.00 | +0.2% | |
| Nov 27, 2018 | EBS Emergent Biosolutions Inc. | Bailey Sue | Director | Sell | 17,717 | $69.62 | $1,233,452.22 | -8.3% | |
| Nov 27, 2018 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 184,000 | $4.83 | $889,088.00 | -0.5% | |
| Nov 27, 2018 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 45,832 | $69.79 | $3,198,698.88 | -1.6% | |
| Nov 26, 2018 | AQST Aquestive Therapeutics, Inc. | Wood Theresa | Svp-hr And Org. Development | Buy | 500 | $10.34 | $5,170.00 | +0.6% | |
| Nov 26, 2018 | NBIX Neurocrine Biosciences Inc | Pops Richard F57 | Director | Sell | 4,124 | $91.37 | $376,789.67 | -12.3% | |
| Nov 23, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob47 | SVP Corp Admin Center | Sell | 1,299 | $20.26 | $26,314.75 | -3.4% | |
| Nov 23, 2018 | JNJ Johnson & Johnson | Sneed Michael E | EVP, Global Corp Aff &COO | Sell | 30,943 | $142.46 | $4,407,985.07 | -43.7% | |
| Nov 23, 2018 | AQST Aquestive Therapeutics, Inc. | Kendall Keith J | CEO And President | Buy | 7,950 | $10.10 | $80,325.00 | +0.6% | |
| Nov 23, 2018 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 15,500 | $9.32 | $144,420.00 | -3.6% | |
| Nov 21, 2018 | AQST Aquestive Therapeutics, Inc. | Boyd Peter E.84 | Svp-operations/ Value Delivery | Buy | 200 | $9.98 | $1,996.00 | +0.4% | |
| Nov 21, 2018 | AQST Aquestive Therapeutics, Inc. | Marshall Ken W. | Commercial Leader | Buy | 1,445 | $10.15 | $14,666.75 | New | |
| Nov 21, 2018 | AQST Aquestive Therapeutics, Inc. | Maxwell John T. | Svp-chief Financial Officer | Buy | 10,000 | $9.80 | $98,000.00 | +7.2% | |
| Nov 21, 2018 | BCRX Biocryst Pharmaceuticals Inc | Powell Lynne | Senior VP - CCO | Sell | 14,455 | $9.05 | $130,839.55 | -85.5% | |
| Nov 21, 2018 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Buy | 1,000 | $10.25 | $10,250.00 | - | |
| Nov 20, 2018 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 35,173 | $69.75 | $2,453,365.19 | -1.2% | |
| Nov 20, 2018 | BCRX Biocryst Pharmaceuticals Inc | Powell Lynne | Senior VP - CCO | Sell | 15,470 | $8.55 | $132,315.44 | -44.0% | |
| Nov 20, 2018 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Sell | 182,800 | $4.74 | $866,746.20 | -1.4% | |
| Nov 20, 2018 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 11,198 | $8.67 | $97,116.61 | -2.6% | |
| Nov 19, 2018 | TLPH Talphera, Inc. | Palmer Pamela P | Chief Medical Officer | Buy | 16,000 | $3.07 | $49,120.00 | +3.5% | |
| Nov 19, 2018 | PBH Prestige Consumer Healthcare Inc. | Connors Timothy | EVP, Sales &Marketing | Sell | 34,000 | $38.25 | $1,300,500.00 | -56.9% | |
| Nov 19, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 195,000 | $115.31 | $22,485,572.10 | - | |
| Nov 19, 2018 | PCRX Pacira Biosciences, Inc. | Wicki Andreas71 | Director | Sell | 990 | $47.08 | $46,605.34 | -0.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.